Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Mostrar outras versões (1)

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F
Formato:	Journal article
Idioma:	English
Publicado em:	2014

Registros relacionados

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
por: Ruiz Garcia, V, et al.
Publicado em: (2011)

Certolizumab pegol in therapy for rheumatoid arthritis
por: Galina Viktorovna Lukina, et al.
Publicado em: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
por: M Connock, et al.
Publicado em: (2010-10-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
por: Vera Nikolayevna Amirdjanova, et al.
Publicado em: (2012-10-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
por: Evgeniy L'vovich Nasonov, et al.
Publicado em: (2011-02-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
por: Emna Hannech, et al.
Publicado em: (2021-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
por: Dmitry Evgenyevich Karateev, et al.
Publicado em: (2012-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
por: T. V. Korotaeva, et al.
Publicado em: (2015-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
por: Maria Majdan, et al.
Publicado em: (2014-07-01)

Certolizumab pegol in the treatment of spondyloarthritis
por: Mariusz Korkosz
Publicado em: (2014-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
por: Smolen, JS, et al.
Publicado em: (2024)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
por: Purcaru, O, et al.
Publicado em: (2010)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
por: J Rosa, et al.
Publicado em: (2010-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
por: Sh. F. Erdes
Publicado em: (2016-02-01)

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
por: Andrea Bassi, et al.
Publicado em: (2023-04-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
por: José Alexandre Mendonça, et al.
Publicado em: (2019-02-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
por: Stéphane Paul, et al.
Publicado em: (2020-07-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Mehmet Baysal, et al.
Publicado em: (2018-09-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
por: Lindsey J. Wanberg, et al.
Publicado em: (2024-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
por: Tanaka, Y, et al.
Publicado em: (2023)

Experience with long-term use of certolizumab pegol (Cimzia)
por: Karine Arnoldovna Lytkina, et al.
Publicado em: (2013-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
por: Karine Arnoldovna Lytkina, et al.
Publicado em: (2013-10-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
por: Ian R White, et al.
Publicado em: (2022-01-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
por: Ian R. White, et al.
Publicado em: (2022-01-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
por: Vivian P. Bykerk, et al.
Publicado em: (2023-02-01)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
por: Glatt, S, et al.
Publicado em: (2019)

Quantitation of certolizumab pegol by validated liquid chromatography methods
por: Clóvis Dervil Appratto Cardoso Júnior, et al.
Publicado em: (2023-11-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
por: I.L. Khalif, et al.
Publicado em: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga S, et al.
Publicado em: (2014-02-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
por: Piotr Wiland, et al.
Publicado em: (2011-08-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
por: Acosta-Felquer ML, et al.
Publicado em: (2016-03-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
por: P. I. Novikov, et al.
Publicado em: (2018-07-01)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
por: Hazes, J, et al.
Publicado em: (2010)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
por: A. Spadaro, et al.
Publicado em: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
por: Wojciech Blonski, et al.
Publicado em: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
por: O V Knyazev, et al.
Publicado em: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
por: Yael Sharon, et al.
Publicado em: (2020-06-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
por: R. Talotta, et al.
Publicado em: (2016-09-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
por: Syuichi Koarada, et al.
Publicado em: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
por: Jeffrey R. Curtis, et al.
Publicado em: (2017-12-01)